Abstract:Background The complement system is highly activated in primary membranous nephropathy (MN). Identifying the complement components that damage podocytes has important therapeutic implications. This study investigated the role of C3a and the C3a receptor (C3aR) in the pathogenesis of MN. Methods C3aR expression in kidneys and circulating levels of C3a of MN patients were examined. Human podocyte damage was assessed after exposure to MN plasma +/− C3aR blockade (SB290157, JR14a). C3aR antagonists were administered to rats with Heymann nephritis on day 0 or after proteinuria. Clinical and pathologic parameters, specific IgG and complement activation, and podocyte injuries were then assessed. Results In the glomeruli, C3aR staining merged well with podocin. Overexpression of C3aR correlated positively with proteinuria, serum creatinine, and no response to treatments. Human podocytes exposed to MN plasma showed increased expression of PLA2R, C3aR, and Wnt3/ β -catenin, reduced expression of synaptopodin and migration function, downregulated Bcl-2, and decreased cell viability. C3aR antagonists could block these effects. In Heymann nephritis rats, C3aR blockade attenuated proteinuria, electron-dense deposition, foot process width, and glomerular basement membrane thickening in glomeruli. The increased plasma C3a levels and overexpression of C3aR were also alleviated. Specific, but not total, IgG levels decreased, with less deposition of rat IgG in glomeruli and subsequent reduction of C1q, factor B, and C5b-9. Conclusion C3a anaphylatoxin is a crucial effector of complement-mediated podocyte damage in MN. The C3aR antagonist may be a potentially viable treatment for this disease. Significance Statement Membranous nephropathy (MN) is the leading cause of adult nephrotic syndrome, in which the complement system is highly activated. This paper describes the discovery that the C3a/C3aR pathway is a crucial effector of complement-mediated podocyte injuries in MN. Levels of plasma C3a and glomerular C3aR are elevated in patients with MN compared with healthy controls and are associated with severity and prognosis. In vitro , C3a from MN patients' plasma damages the physiologic function and cellular activity of podocytes, which C3aR antagonists block. In vivo , C3aR antagonists can also attenuate renal injuries of Heymann nephritis (a classic disease model of MN) rats. Collectively, C3aR blockade may be a potentially viable treatment for this disease. Visual

Complement C3a and C3a Receptor Activation Mediates Podocyte Injuries in the Mechanism of Primary Membranous Nephropathy